Europe Closed Systems Drug Transfer Devices Market Growth and Recent Trends by 2027

The Europe closed systems drug transfer devices market is expected to reach US$ 487.58 million by 2027 from US$ 112.01 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2019 to 2027.

Driving factors include growing adoption of chemotherapy and improvement of regulatory guidelines regarding hazardous drugs. However, the lack of standards and product safety issues may restrain the market growth.

The closed system drug transfer devices provide protection against hazardous drugs or vapors during drug preparation and administration. It comprises components which enables filtering of dangerous vapors out of the system. Closed system drug transfer devices play a major role in protection of healthcare professionals from antineoplastic as well as other harmful medications. Growing emphasis on implementation of occupational health and safety standards by government authorities are offering lucrative opportunity for growth of the market.

Closed system drug transfer devices provide superior protection against exposure to potentially hazardous drugs during the compounding and administration. Therefore, government agencies and healthcare authorities are emphasizing on the utilization of these devices. There are several guidelines for safe handling of hazardous drugs including those issued by the UK Health and Safety Executive (HSE), and NHS Pharmaceutical Quality Assurance Committee.  For instance, In the UK, the NHS Pharmaceutical Quality Assurance (NHSPQA) committee recently published recommendations for safe handling of cytotoxic drugs in clinical areas. The NHSPQA took short-term actions which were need to be taken to reduce the risks of exposure for healthcare workers, including the application of CSTDs. Moreover, these guidelines broadly recommend the identification of the risk, use of biological safety cabinets, use of closed‐system drug‐transfer devices where reasonably practicable, and control of exposure at source. Thus, these policies are formulated to protect healthcare professionals and patients. Moreover, the newly issued regulations are applicable to all healthcare professionals and facilities dealing with dangerous drugs.

The market for closed system drug transfer device (CSTD) in Europe is highly affected. In addition, many patients have been fearful of exposure to SARS-CoV-2 or of overburdening healthcare services and thus have been less likely to present to healthcare services for cancer screening and diagnosis. As approximately one in five cancers is diagnosed in emergency presentations, this is likely to be responsible for considerably delayed diagnoses. Additionally, NHS England is consolidating cancer surgery in cancer hubs kept as free as possible from SARS-CoV-2 exposure thereby increasing the adoption of CTSD’s to avoid exposure to the hazardous drugs.

Rest of Europe Closed Systems Drug Transfer Devices Market, Revenue and Forecast to 2027 (US$ Mn)

EUROPE CLOSED SYSTEMS DRUG TRANSFER DEVICES MARKET SEGMENTATION

By Closing Mechanism

• Push-to-turn Systems
• Luer-lock Systems
• Color-to-color Alignment Systems
• Click-to-lock Systems

By Type

• Membrane-to-membrane Systems
• Needleless Systems

By Technology

• Diaphragm-based Devices
• Compartmentalized Devices
• Air Cleaning/Filtration Devices

By Component

• Vial Access Devices
• Syringe Safety Devices
• Bag/Line Access Devices
• Accessories

By End User

• Hospitals and Clinics
• Oncology Centers
• Others

By Country

• Germany
• UK
• France
• Italy
• Spain

Company Profiles

• Caragen Ltd.
• BD
• B. Braun Medical Inc
• ICU MEDICAL INC
• EQUASHIELD

Europe Closed Systems Drug Transfer Devices Report Scope